Vimarsana
Biggest News Aggregation in the World

Page 38 - Path Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Path Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Path Inc Today - Breaking & Trending Today

servicePath welcomes Charles Todd to their Advisory Board - Vimarsana News

servicePath welcomes Charles Todd to their Advisory Board

Recognized Quote-to-Cash Thought Leader Reinforces Fast-Growing Company’s Opportunity to Capitalize on Broadening Market Demand and Accelerate Global Growth

These Were The Five Best And Worst Performing Large-Cap Stocks In Q1 2022 - Vimarsana News

These Were The Five Best And Worst Performing Large-Cap Stocks In Q1 2022

We have used the Q1 return data to come up with the five best performing large-cap stocks in Q1 2022 and worst performing large-cap stocks in Q1 2022.

Cramer's Lightning Round: I Can't Recommend UiPath - Vimarsana News

Cramer's Lightning Round: I Can't Recommend UiPath

“Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.

UiPath (NASDAQ:PATH) Downgraded to "Strong Sell" at Zacks Investment Research - Vimarsana News

UiPath (NASDAQ:PATH) Downgraded to "Strong Sell" at Zacks Investment Research

Zacks Investment Research cut shares of UiPath (NASDAQ:PATH – Get Rating) from a hold rating to a strong sell rating in a research note published on Thursday morning, Zacks.com reports. According to Zacks, “UiPath Inc. offers an end-to-end platform for automation, combining Robotic Process Automation solution for digital business operations. UiPath Inc. is based in […]

UiPath (NASDAQ:PATH) Price Target Cut to $55.00 by Analysts at Truist Financial - Vimarsana News

UiPath (NASDAQ:PATH) Price Target Cut to $55.00 by Analysts at Truist Financial

UiPath (NASDAQ:PATH – Get Rating) had its target price reduced by Truist Financial from $75.00 to $55.00 in a report released on Thursday morning, The Fly reports. Truist Financial currently has a buy rating on the healthcare company’s stock. A number of other research firms have also weighed in on PATH. Wells Fargo & Company […]